Use of botulinum toxin in musculoskeletal pain

Jasvinder A Singh, Jasvinder A Singh

Abstract

Chronic musculoskeletal pain is a common cause of chronic pain, which is associated with a total cost of $635 billion per year in the U.S. Emerging evidence suggests an anti-nociceptive action of botulinum toxin, independent of its muscle paralyzing action. This review provides a summary of data from both non-randomized and randomized clinical studies of botulinum toxin in back pain and various osteoarticular conditions, including osteoarthritis, tennis elbow, low back pain and hand pain. Three randomized controlled trials (RCTs) of small sizes provide evidence of short-term efficacy of a single intra-articular injection of 100 units of botulinum toxin A (BoNT/A) for the relief of pain and the improvement of both function and quality of life in patients with chronic joint pain due to arthritis. Three RCTs studied intramuscular BoNT/A for tennis elbow with one showing a significant improvement in pain relief compared with placebo, another one showing no difference from placebo, and the third finding that pain and function improvement with BoNT/A injection were similar to those obtained with surgical release. One RCT of intramuscular BoNT/A for low back pain found improvement in pain and function compared to placebo. Single RCTs using local injections of BoNT in patients with either temporomandibular joint (TMJ) pain or plantar fasciitis found superior efficacy compared to placebo. One RCT of intramuscular BoNT/B in patients with hand pain and carpal tunnel syndrome found improvement in pain in both BoNT/B and placebo groups, but no significant difference between groups. Most evidence is based on small studies, but the use of BoNT is supported by a single, and sometimes up to three, RCTs for several chronic musculoskeletal pain conditions. This indicates that botulinum toxin may be a promising potential new treatment for chronic refractory musculoskeletal pain. Well-designed large clinical trials are needed.

Conflict of interest statement

Competing interests: There are no financial competing interests related directly to this study. JAS has received research and travel grants from Takeda, Savient, and Allergan; and consultant fees from URL pharmaceuticals, Savient, Takeda, Regeneron, Ardea, Allergan and Novartis. The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

References

    1. Institute of Medicine: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, D.C.: The National Academies Press;2011.
    1. Breivik H, Collett B, Ventafridda V, et al. : Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333 10.1016/j.ejpain.2005.06.009
    1. CDC: Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation – United States, 2007–2009. MMWR Morb Mortal Wkly Rep. 2010;59(39):1261–5
    1. CDC: Prevalence and most common causes of disability among adults – United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58(16):421–6
    1. Stoddard S, Jans L, Ripple JM, et al. : Chartbook on work and disability in the United States, 1998. Washington, DC: US National Institute on Disability and Rehabilitation Research;1998.
    1. Helmick CG, Felson DT, Lawrence RC, et al. : Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25 10.1002/art.23177
    1. United States Bone and Joint Decade: The Burden of Musculoskeletal Diseases in the United States. Rosemont, IL; American Academy of Orthopaedic Surgeons [Data Source: 2004 National Ambulatory Medical Care Survey (NAMCS) and the 1997 National Hospital Ambulatory Medical Care Survey (NHAMCS)]. Rosemont, IL: USBJD;2008[12/20/2012].
    1. CDC: National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions–United States, 2003. MMWR Morb Mortal Wkly Rep. 2007;56(1):4–7
    1. Hart LG, Deyo RA, Cherkin DC: Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine (Phila Pa 1976). 1995;20(1):11–19 10.1097/00007632-199501000-00003
    1. Deyo RA, Mirza SK, Martin BI: Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine (Phila Pa 1976). 2006;31(23):2724–7 10.1097/
    1. Lawrence RC, Helmick CG, Arnett FC, et al. : Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778–99 10.1002/1529-0131(199805)41:5<778::AID-ART4>;2-V
    1. Frymoyer JW, Cats-Baril WL: An overview of the incidences and costs of low back pain. Orthop Clin North Am. 1991;22(2):263–71
    1. Katz JA: Getting the lowdown on back pain. Nursing. 2001;31(12):24
    1. Schaible HG: Why does an inflammation in the joint hurt? Br J Rheumatol. 1996;35(5):405–6 10.1093/rheumatology/35.5.405
    1. Schaible HG: Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol. 2007; (177):3–28 10.1007/978-3-540-33823-9_1
    1. Schaible HG, Ebersberger A, Von Banchet GS: Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002;966:343–54 10.1111/j.1749-6632.2002.tb04234.x
    1. Schaible HG, Schmelz M, Tegeder I: Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev. 2006;58(2):323–42 10.1016/j.addr.2006.01.011
    1. Schaible HG, Richter F, Ebersberger A, et al. : Joint pain. Exp Brain Res. 2009;196(1):153–62 10.1007/s00221-009-1782-9
    1. Neugebauer V, Lücke T, Schaible HG: N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J Neurophysiol. 1993;70(4):1365–77
    1. Schaible HG, Schmidt RF, Willis WD: Enhancement of the responses of ascending tract cells in the cat spinal cord by acute inflammation of the knee joint. Exp Brain Res. 1987;66(3):489–99 10.1007/BF00270681
    1. Schaible HG, Del Rosso A, Matucci-Cerinic M: Neurogenic aspects of inflammation. Rheum Dis Clin North Am. 2005;31(1):77–101, ix. 10.1016/j.rdc.2004.09.004
    1. Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2(12):973–85 10.1038/nrd1251
    1. Watkins LR, Milligan ED, Maier SF: Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol. 2003;521:1–21
    1. Watkins LR, Maier SF: Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002;82(4):981–1011 10.1152/physrev.00011.2002
    1. Woolf CJ, Allchorne A, Safieh-Garabedian B, et al. : Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 1997;121(3):417–24 10.1038/sj.bjp.0701148
    1. Woolf CJ, Safieh-Garabedian B, Ma QP, et al. : Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62(2):327–31 10.1016/0306-4522(94)90366-2
    1. Woolf C, Wiesenfeld-Hallin Z: Substance P and calcitonin gene-related peptide synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neurosci Lett. 1986;66(2):226–30 10.1016/0304-3940(86)90195-3
    1. Jones SL: Descending noradrenergic influences on pain. Prog Brain Res. 1991;88:381–94 10.1016/S0079-6123(08)63824-8
    1. Willis WD, Westlund KN: Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol. 1997;14(1):2–31 10.1097/00004691-199701000-00002
    1. Woolf CJ: American College of Physicians; American Physiological Society: Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441–51
    1. Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999;96(14):7723–30 10.1073/pnas.96.14.7723
    1. Woolf CJ, Decosterd I: Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain. 1999;82(Suppl 6):S141–7 10.1016/S0304-3959(99)00148-7
    1. Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353(9168):1959–64 10.1016/S0140-6736(99)01307-0
    1. Ge Z, Hu Y, Heng BC, et al. : Osteoarthritis and therapy. Arthritis Rheum. 2006;55(3):493–500 10.1002/art.21994
    1. Zhang W, Moskowitz RW, Nuki G, et al. : OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–62 10.1016/j.joca.2007.12.013
    1. Zhang W, Moskowitz RW, Nuki G, et al. : OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15(9):981–1000 10.1016/j.joca.2007.06.014
    1. Bellamy N, Campbell J, Robinson V, et al. : Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006; (2):CD005328 10.1002/14651858.CD005328.pub2
    1. Bellamy N, Campbell J, Robinson V, et al. : Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006; (2):CD005321 10.1002/14651858.CD005321.pub2
    1. van der Windt DA, Bouter LM: Physiotherapy or corticosteroid injection for shoulder pain? Ann Rheum Dis. 2003;62(5):385–7 10.1136/ard.62.5.385
    1. Green S, Buchbinder R, Glazier R, et al. : Interventions for shoulder pain. Cochrane Database Syst Rev. 2000; (2):CD001156 10.1002/14651858.CD001156
    1. Rains C, Bryson HM: Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7(4):317–28 10.2165/00002512-199507040-00007
    1. Jamtvedt G, Dahm KT, Christie A, et al. : Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews. Phys Ther. 2008;88(1):123–36 10.2522/ptj.20070043
    1. Birklein F, Schmelz M: Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett. 2008;437(3):199–202 10.1016/j.neulet.2008.03.081
    1. Cui M, Khanijou S, Rubino J, et al. : Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1–2):125–33 10.1016/j.pain.2003.10.008
    1. Lucioni A, Bales GT, Lotan TL, et al. : Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70 10.1111/j.1464-410X.2007.07312.x
    1. Purkiss J, Welch M, Doward S, et al. : Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000;59(11):1403–6 10.1016/S0006-2952(00)00260-4
    1. Rapp DE, Turk KW, Bales GT, et al. : Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006;175(3 Pt 1):1138–42 10.1016/S0022-5347(05)00322-8
    1. Durham PL, Cady R, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42; discussion 42-3. 10.1111/j.1526-4610.2004.04007.x
    1. Meng J, Wang J, Lawrence G, et al. : Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(Pt 16):2864–74 10.1242/jcs.012211
    1. Purkiss J, Welch M, Doward S, et al. : Capsicin stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000;59(11):1403–6 10.1016/S0006-2952(00)00260-4
    1. Larsson J, Ekblom A, Henriksson K, et al. : Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol. 1991;20(5):326–35 10.3109/03009749109096808
    1. Kar S, Gibson SJ, Rees RG, et al. : Increased calcitonin gene-related peptide (CGRP), substance P, and enkephalin immunoreactivities in dorsal spinal cord and loss of CGRP-immunoreactive motoneurons in arthritic rats depend on intact peripheral nerve supply. J Mol Neurosci. 1991;3(1):7–18 10.1007/BF02896844
    1. Devillier P, Weill B, Renoux M, et al. : Elevated levels of tachykinin-like immunoreactivity in joint fluids from patients with rheumatic inflammatory diseases. N Engl J Med. 1986;314(20):1323 10.1056/NEJM198605153142018
    1. Ahmed M, Bjurholm A, Schultzberg M, et al. : Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radioimmunoassay analysis. Arthritis Rheum. 1995;38(5):699–709 10.1002/art.1780380519
    1. Krämer HH, Angerer C, Erbguth F, et al. : Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003;250(2):188–93 10.1007/s00415-003-0971-x
    1. Yuan RY, Sheu JJ, Yu JM, et al. : Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–8 10.1212/
    1. Ranoux D, Attal N, Morain F, et al. : Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–83 10.1002/ana.21427
    1. Sycha T, Samal D, Chizh B, et al. : A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 2006;102(2):509–16 10.1213/01.ane.0000194447.46763.73
    1. Blersch W, Schulte-Mattler WJ, Przywara S, et al. : Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002;205(1):59–63 10.1016/S0022-510X(02)00313-1
    1. Voller B, Sycha T, Gustorff B, et al. : A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61(7):940–4 10.1212/01.WNL.0000086374.92906.6A
    1. Singh JA: Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Ther Adv Musculoskelet Dis. 2010;2(2):105–18 10.1177/1759720X09357113
    1. Ho KY, Tan KH: Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain. 2007;11(5):519–27 10.1016/j.ejpain.2006.09.002
    1. Cuevas-Trisán RL, Cruz-Jimenez M: The use of botulinum toxin in physical medicine and rehabilitation. Bol Asoc Med P R. 2006;98(1):42–55
    1. Hameed F, Ihm J: Injectable medications for osteoarthritis. PM R. 2012;4(5 Suppl):S75–S81 10.1016/j.pmrj.2012.02.010
    1. Cheng OT, Souzdalnitski D, Vrooman B, et al. : Evidence-based knee injections for the management of arthritis. Pain Med. 2012;13(6):740–753 10.1111/j.1526-4637.2012.01394.x
    1. Sim WS: Application of botulinum toxin in pain management. Korean J Pain. 2011;24(1):1–6 10.3344/kjp.2011.24.1.1
    1. Mahowald ML, Singh JA, Dykstra D: Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006;9(2–3):179–88 10.1007/BF03033937
    1. Singh JA, Mahowald ML, Kushnaryov A, et al. : Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009;15(1):35–8 10.1097/RHU.0b013e3181953b14
    1. Dykstra D, Stuckey M, Schimpff S, et al. : The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sterno-calvicular joint pain and C-2 root and lumbar disc pain: a case series of 11 patients. The Pain Clinic. 2007;19(1):27–32 10.1179/016911107X217473
    1. Singh JA, Mahowald ML, Noorbaloochi S: Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009;153(5):205–16 10.1016/j.trsl.2009.02.004
    1. Farrar JT, Portenoy RK, Berlin JA, et al. : Defining the clinically important difference in pain outcome measures. Pain. 2000;88(3):287–94 10.1016/S0304-3959(00)00339-0
    1. Farrar JT, Young JP, Jr, LaMoreaux L, et al. : Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–58 10.1016/S0304-3959(01)00349-9
    1. Boon AJ, Smith J, Dahm DL, et al. : Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R. 2010;2(4):268–76 10.1016/j.pmrj.2010.02.011
    1. Mahowald ML, Krug HE, Singh JA, et al. : Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. Toxicon. 2009;54(5):658–67 10.1016/j.toxicon.2009.03.028
    1. Singh JA, Mahowald ML: Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009;76(2):190–4 10.1016/j.jbspin.2008.05.006
    1. Morré HH, Keizer SB, van Os JJ: Treatment of chronic tennis elbow with botulinum toxin. Lancet. 1997;349(9067):1746 10.1016/S0140-6736(05)62958-3
    1. Hayton MJ, Santini AJ, Hughes PJ, et al. : Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am. 2005;87(3):503–7 10.2106/JBJS.D.01896
    1. Singh JA, Mahowald ML, Noorbaloochi S: Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010;37(11):2377–86 10.3899/jrheum.100336
    1. Wong SM, Hui AC, Tong PY, et al. : Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143(11):793–7 10.7326/0003-4819-143-11-200512060-00007
    1. Keizer SB, Rutten HP, Pilot P, et al. : Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clin Orthop Relat Res. 2002; (401):125–31 10.1097/00003086-200208000-00015
    1. Lin YC, Tu YK, Chen SS, et al. : Comparison between botulinum toxin and corticosteroid injection in the treatment of acute and subacute tennis elbow: a prospective, randomized, double-blind, active drug-controlled pilot study. Am J Phys Med Rehabil. 2010;89(8):653–9 10.1097/PHM.0b013e3181cf564d
    1. Placzek R, Drescher W, Deuretzbacher G, et al. : Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am. 2007;89(2):255–60 10.2106/JBJS.F.00401
    1. von Lindern JJ: Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg. 2001;101(1):39–41
    1. Freund B, Schwartz M, Symington JM: Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000;38(5):466–71 10.1054/bjom.1999.0238
    1. Freund B, Schwartz M, Symington JM: The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg. 1999;57(8):916–20; discussion 920-1. 10.1016/S0278-2391(99)90007-1
    1. von Lindern JJ, Niederhagen B, Bergé S, et al. : Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61(7):774–8 10.1016/S0278-2391(03)00153-8
    1. Ney JP, Difazio M, Sichani A, et al. : Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain. 2006;22(4):363–9 10.1097/01.ajp.0000174267.06993.3f
    1. Liu Z: [Botulinum toxin A (BTX-A) point injection for treatment of the third lumbar transverse process syndrome]. Zhongguo Zhen Jiu. 2008;28(5):337–9
    1. Foster L, Clapp L, Erickson M, et al. : Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56(10):1290–3 10.1046/j.1533-2500.2001.1039_30.x
    1. De Andres J, Adsuara VM, Palmisani S, et al. : A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35(3):255–60 10.1097/AAP.0b013e3181d23241
    1. Fishman LM, Anderson C, Rosner B: BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil. 2002;81(12):936–42 10.1097/01.PHM.0000034956.35609.5E
    1. Placzek R, Deuretzbacher G, Buttgereit F, et al. : Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up. Ann Rheum Dis. 2005;64(11):1659–61 10.1136/ard.2005.035840
    1. Babcock MS, Foster L, Pasquina P, et al. : Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005;84(9):649–54 10.1097/01.phm.0000176339.73591.d7
    1. Breuer B, Sperber K, Wallenstein S, et al. : Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med. 2006;7(1):16–24 10.1111/j.1526-4637.2006.00084.x
    1. Singer BJ, Silbert PL, Dunne JW, et al. : An open label pilot investigation of the efficacy of Botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain. Disabil Rehabil. 2006;28(11):707–13 10.1080/09638280500301477
    1. Marchini C, Acler M, Bolognari MA, et al. : Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results. J Rehabil Med. 2010;42(7):691–3 10.2340/16501977-0546
    1. Lim JY, Koh JH, Paik NJ: Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke. 2008;39(1):126–31 10.1161/STROKEAHA.107.484048
    1. Anderson S, Krug H, Dorman C, et al. : Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain. J Pain Res. 2010;3:161–8 10.2147/JPR.S12520

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere